Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
The 15q11-q13 microduplication (dup15q11-q13) syndrome is characterized by neurobehavioral disorders, hypotonia, cognitive deficit, language delay and seizures. Prevalence is unknown.
Features include always present findings: Bilateral tonic-clonic seizure, Echolalia, Severe intellectual disability, and Reduced eye contact and others; and very common findings: Low muscle tone (hypotonia), Intellectual disability, Delayed speech and language development, and Compulsive behaviors and others. 34 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 12 | Bilateral tonic-clonic seizure, Seizure, Severe intellectual disability |
Arms and legs | 2 | Clinodactyly of the 5th finger, Finger syndactyly |
Muscles | 1 | Low muscle tone (hypotonia) |
Head and neck | 1 | Macrocephaly |
Growth and development | 1 | Short stature |
Bones and joints | 1 | Joint hypermobility |
Maternal 15q duplication syndrome (maternal dup15q) is characterized by hypotonia and motor delays, intellectual disability, autism spectrum disorder (ASD), and epilepsy including infantile spasms. These clinical findings differ significantly between people with a maternal interstitial duplication and those with a maternal isodicentric supernumerary chromosome, or idic(15). Those with a maternal idic(15) are typically more severely affected than those with an interstitial duplication. However, severity varies even among individuals who have increased dosage by the same genetic mechanism. Some phenotypic features, such as ASD, are more consistently observed in individuals with a maternal idic(15) or large (5-Mb) interstitial duplications that extend beyond the PWACR . Table 2. Maternal 15q Interstitial Duplication and Idic(15): Comparison of Clinical Features
Feature | Maternal Interstitial Duplication | Maternal Isodicentric Supernumerary Chromosome |
|---|---|---|
Hypotonia | Mild to moderate | Severe Developmental delay/ |
Maternal 15q duplication syndrome (maternal dup15q) should be suspected in individuals with the following clinical features:
Moderate-to-severe hypotonia in infancy and early delays in reaching motor milestones
Developmental delay that includes not only motor but also language
Intellectual disability (ID)
Autism spectrum disorder (ASD)
Seizures, particularly infantile spasms
Dysmorphic features including upturned nose, epicanthal folds, and downslanting palpebral fissures
Behavioral difficulties including hyperactivity, anxiety, or emotional lability
A characteristic EEG biomarker involving excessive beta oscillations (12–30Hz)
The diagnosis of maternal dup15q is established in a proband by detection of at least one extra maternally derived copy o...
Source: GeneReviews — "Maternal 15q Duplication Syndrome"
Phenotypic features associated with maternal 15q duplication syndrome (maternal dup15q) are not sufficient for diagnosis. All chromosome anomalies and genes known to be associated with intellectual disability (ID) should be included in the differential diagnosis of maternal dup15q. See OMIM Autosomal Dominant, Autosomal Recessive, Nonsyndromic X-Linked, and Syndromic X-Linked Intellectual Developmental Disorder Phenotypic Series.
Source: GeneReviews — "Maternal 15q Duplication Syndrome"
Biomarker and diagnostic research for 15q11q13 microduplication syndrome has been reported in the published literature.
No approved treatments are currently available for 15q11q13 microduplication syndrome. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with maternal 15q duplication syndrome (maternal dup15q), the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended. Table 4 Recommended Evaluations Following Initial Diagnosis in Individuals with Maternal 15q Duplication Syndrome
System/Concern | Evaluation | Comment |
|---|---|---|
Neurologic | Neurologic eval | Consider EEG if seizures are a concern. |
Ataxia | Orthopedics / physical medicine rehab/ PT OT eval | To incl assessment of:; Gross motor fine motor skills; Mobility, ADL, need for adaptive devices; Need for PT (to improve gross motor skills) /or OT (to improve fine motor skills) |
Development | Developmental assessment | To incl motor, adaptive, cognitive, speech-language eval; Eval for early intervention/ special education Psychiatric/ |
Behavioral | Neuropsychiatric eval | For persons age 12 mos: screening for concerns incl sleep disturbances, ADHD, anxiety, /or findings suggestive of ASD Genetic |
counseling | By genetics professionals1 |
Source: GeneReviews — "Maternal 15q Duplication Syndrome"
Seizure triggers (e.g., sleep deprivation, stress, and failure to follow medication regimen) should be avoided.
Source: GeneReviews — "Maternal 15q Duplication Syndrome"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Maternal 15q Duplication Syndrome"
View trials for 15q11q13 microduplication syndrome
Table 6.
Recommended Surveillance for Individuals with Maternal 15q Duplication Syndrome
System/Concern | Evaluation | Frequency
| • Measurement of growth parameters
Eval of nutritional status safety of oral intake
| At each visit
| • Monitor those w/seizures as clinically indicated.
Assess for new manifestations such as seizures, changes in tone, movement disorders.
| Monitor developmental progress educational needs.
Psychiatric/
| Behavioral assessment for anxiety, attention, aggressive or self-injurious behavior
| Physical medicine, OT/PT assessment of mobility, self-help skills
Family/
| Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources) care coordination.
OT = occupational therapy; PT = physical therapy
Source: GeneReviews — "Maternal 15q Duplication Syndrome"
Phenotype severity distribution: 10 always present features, 6 very common features, 6 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for 15q11q13 microduplication syndrome.
12 publications have been identified in PubMed for 15q11q13 microduplication syndrome. Research spans Case Report / Case Series (50%), Review / Meta-Analysis (25%), and Diagnostic / Biomarker (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 6 | 50% |
Research summaries | 3 | 25% |
Testing and diagnosis research | 2 | 17% |
Laboratory research | 1 | 8% |
Liu RY (2026). [PMID: 41730779](https://pubmed.ncbi.nlm.nih.gov/41730779/). *American journal of medical genetics. Part A*. [Basic Science / Preclinical]
Colijn MA (2026). [PMID: 41320189](https://pubmed.ncbi.nlm.nih.gov/41320189/). *Journal of intellectual disability research : JIDR*. [Case Report / Case Series]
Gupta PK (2025). [PMID: 40250721](https://pubmed.ncbi.nlm.nih.gov/40250721/). *Neurobiology of disease*. [Case Report / Case Series]
Wu K (2025). [PMID: 41048353](https://pubmed.ncbi.nlm.nih.gov/41048353/). *Frontiers in neuroscience*. [Case Report / Case Series]
Xu J (2025). [PMID: 41272673](https://pubmed.ncbi.nlm.nih.gov/41272673/). *BMC medical genomics*. [Review / Meta-Analysis]
Ma Y (2025). [PMID: 40383644](https://pubmed.ncbi.nlm.nih.gov/40383644/). *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians*. [Review / Meta-Analysis]
Venezia I (2025). [PMID: 41114666](https://pubmed.ncbi.nlm.nih.gov/41114666/). *Journal of developmental and behavioral pediatrics : JDBP*. [Review / Meta-Analysis]
Peng H (2025). [PMID: 40229547](https://pubmed.ncbi.nlm.nih.gov/40229547/). *Scientific reports*. [Diagnostic / Biomarker]
Vieira DKR (2024). [PMID: 39766813](https://pubmed.ncbi.nlm.nih.gov/39766813/). *Genes*. [Case Report / Case Series]
Zhang Y (2024). [PMID: 39344625](https://pubmed.ncbi.nlm.nih.gov/39344625/). *Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics*. [Diagnostic / Biomarker]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 4:02 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
intellectual disability | Moderate | Severe |
Autism spectrum disorder | ≥50%1,2 | ≥80%1,3 |
Epilepsy | ~25%4 | ~65%4 1. 2. 3. , Hypotonia and motor skills. Hypotonia in newborns and infants with maternal dup15q is associated with feeding difficulties and gross motor delays . Hypotonia also contributes to gastrointestinal issues in maternal dup15q, such as constipation. |
Source: GeneReviews — "Maternal 15q Duplication Syndrome"
Treatment of Manifestations in Individuals with Maternal 15q Duplication Syndrome Manifestation/Concern | Treatment | Considerations/Other Poor weight |
gain / FTT | Feeding therapy; gastrostomy tube placement may be required for persistent feeding issues. | Low threshold for clinical feeding eval /or radiographic swallowing study if clinical signs or symptoms of dysphagia |
DD/ID | See . | Epilepsy |
AI-curated news mentioning 15q11q13 microduplication syndrome
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.